Home Blog Page 1643

Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions

By
Advertorial Desk
-

MELBOURNE, Australia and INDIANAPOLIS, Dec. 22, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides a precision medicine portfolio update in relation to:

  • TLX591-CDx (Illuccix® in approved jurisdictions, 68Ga-PSMA-11): Positive data from Phase 3 study in Chinese patients provides the basis for near-term NDA submission in China.
  • TLX101-CDx (Pixclara®[1], 18F-floretyrosine), PET imaging candidate for glioma: Following collaborative interactions with the FDA, finalizing NDA resubmission and expect to provide a further near-term update on FDA acceptance of the file.
  • TLX250-CDx (Zircaix®[1], 89Zr-DFO-girentuximab), PET imaging candidate for ccRCC: Positive Type A meeting held with the FDA to align on remediation of CMC deficiencies identified in the CRL.

Further details on each of these updates is provided below.

Illuccix China Phase 3 Registration Study

Telix is pleased to announce positive top-line results from its Phase 3 registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11) for prostate cancer imaging in Chinese patients. The Illuccix China[2] trial met its primary endpoint of patient-level positive predictive value (PPV) for the detection of tumors in patients with biochemical recurrence (BCR) of prostate cancer following prior radical prostatectomy or radiation therapy. The study confirms that the clinical experience of TLX591-CDx PSMA-PET[3] imaging in Chinese patients is comparable to that observed in patients studied elsewhere.

Illuccix China is a Phase 3 prospective, open-label, single-arm, multicenter study conducted in collaboration with Telix’s strategic commercial partner for the Greater China region, Grand Pharmaceutical Group Limited (Grand Pharma). The study in 140 patients delivered a strong result for the primary endpoint, with an overall patient-level PPV of 94.8% for the detection of tumors with TLX591-CDx (95% confidence interval [CI]: 85.9%, 98.2%), with the lower bound of the 95% CI (85.9%). The region-level PPV was 100.0% in the prostate bed and in the extra-pelvic soft tissue, lymph nodes, and organ metastases (non-bone); 94.7% in the pelvic region outside of the prostate bed, including lymph nodes; and 87.0% in bone metastases.

In the study, patients with suspected BCR were stratified into groups according to their baseline prostate specific antigen (PSA) levels. TLX591-CDx PSMA-PET imaging demonstrated high PPV in all patient groups, including at very low baseline PSA levels.

Baseline PSA

PPV (95% CI)

≥ 5.0 ng/mL

100.0% (78.5%, 100.0%)

< 5.0 to 2.0 ng/mL

100.0% (67.6%, 100.0%)

< 2.0 to 1.0 ng/mL

90.9% (62.3%, 98.4%)

< 1.0 to 0.5 ng/mL

90.0% (59.6%, 98.2%)

< 0.5 to 0.2 ng/mL

93.3% (70.2%, 98.8%)

More than two-thirds (67.2%) of patients experienced a change in their treatment plan as a consequence of TLX591-CDx PSMA-PET imaging compared with the initial plan at baseline. This outcome confirms that PSMA-PET imaging with TLX591-CDx had a meaningful impact on clinical decision-making in Chinese patients, potentially leading to improved treatment strategies for participants with BCR. Final data from the study will be submitted for peer-reviewed publication.

Dr. David N. Cade, Group Chief Medical Officer, Telix, commented, “This is an outstanding result. The primary endpoint of the study was met decisively, with the positive predictive value significantly exceeding the performance threshold agreed with the Chinese regulator. Importantly, the high PPV was consistent even in patients with very low PSA values, and across differing metastatic locations, demonstrating broad clinical applicability. These compelling data will enable Telix and our partner Grand Pharma to submit a New Drug Application for Illuccix in China, a strategically important market.”

In China, more than 134,000 men were diagnosed with prostate cancer in 2022[4], increasing by approximately 6% each year[5]. In line with government policy supporting wider geographic access to nuclear medicine, the number of PET/CT cameras installed in China is expected to surpass 1,600 by the end of 2025[6], compared with 133 in 2010[7].

FDA Resubmission Update: TLX101-CDx

Telix advises that its New Drug Application (NDA) resubmission for TLX101-CDx, (Pixclara®[1], 18F-floretyrosine) to the United States (U.S.) Food and Drug Administration (FDA), is progressing well. The Company has had collaborative interactions with the FDA around providing additional clinical data and a revised statistical analysis plan.

Following a productive Type A meeting to review the basis of the Complete Response Letter (CRL)[8], Telix is currently finalizing its package for resubmission. The Company will provide a further near-term update when the resubmission has been filed and accepted by the FDA. The approved Expanded Access Program (EAP)[9] remains active for TLX101-CDx, reflective of Telix’s commitment to serving patients.

FDA Resubmission Update: TLX250-CDx

Telix has recently participated in a Type A meeting to discuss the CRL it received following review of the Biologics License Application (BLA)[10] for TLX250-CDx (Zircaix®[1], 89Zr-DFO-girentuximab). Telix believes it has reached alignment with the FDA on the remediation of identified deficiencies regarding the product’s chemistry, manufacturing, and controls (CMC) package, which formed the substantive basis of the CRL.

The FDA has collaboratively granted Telix an additional meeting in January to review Telix’s plan for the additional data requested to establish comparability between the drug product used in the ZIRCON Phase 3 clinical trial[11] and the scaled-up manufacturing process intended for commercial use. Telix will provide a further update following receipt of the official FDA meeting minutes of both Type A meetings. The approved Expanded Access Program (EAP)[12] remains active for TLX250-CDx, reflective of Telix’s commitment to serving patients.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix’s first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the U.S. FDA[13].

TLX101-CDx is Telix’s PET imaging candidate for glioma, a rare and life-threatening brain cancer. TLX250-CDx is Telix’s PET imaging candidate for the diagnosis and characterization of clear cell renal cell carcinoma, the most common kidney cancer subtype. TLX101-CDx and TLX250-CDx have not received a marketing authorization in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook

Telix Investor Relations (Global)

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Telix Investor Relations (U.S.)

Annie Kasparian 
Telix Pharmaceuticals Limited 
Director Investor Relations and Corporate Communications 
Email: annie.kasparian@telixpharma.com 

Media Contact

Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-CDx and the planned BLA resubmission for TLX250-CDx, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2025 Telix Pharmaceuticals Limited. All rights reserved.

[1] Brand name subject to final regulatory approval.

[2] ClinicalTrials.gov ID: NCT05847348.

[3] Imaging of prostate-specific membrane antigen with positron emission tomography.

[4] Global Cancer Statistics 2022: GLOBOCAN survey. Published August 2024.

[5] Ye Dingwei et al. Lancet Oncology, 2022.

[6] Yang et al. J Nuc. Med. 2024.

[7] Goetz Partners research 2020.

[8] Telix ASX disclosure 28 April 2025.

[9] ClinicalTrials.gov ID: NCT06743100.

[10] Telix ASX disclosure 28 August 2025.

[11] ClinicalTrials.gov ID: NCT03849118.

[12] ClinicalTrials.gov ID: NCT06090331.

[13] Telix ASX disclosure 21 March 2025.

 

T-MAXIMUM Pharmaceutical’s Allogeneic CAR-T Therapy MT027 Receives FDA IND Clearance to Proceed to Phase II clinical Trial for Recurrent Glioblastoma

By
Advertorial Desk
-

BEIJING, Dec. 21, 2025 /PRNewswire/ — T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial for the treatment of recurrent glioblastoma (rGBM). This milestone marks a significant breakthrough in addressing one of the most formidable challenges in oncology: developing effective allogeneic CAR-T therapies for solid tumors.

“The FDA’s clearance of the IND for MT027 represents a strong validation of our strategic commitment to tackling the most challenging solid tumors,” said Dr. Xiaoyun Shang, Founder and CEO of T-MAXIMUM Pharmaceutical. “This milestone is not only a small step for T-MAXIMUM, but a significant leap forward for the entire cell therapy field as we push into the ‘uncharted territory’ of solid tumor treatment. The successful development and advancement of MT027 is grounded in our deep understanding of immunology and our decisive investment in allogeneic cell-editing technologies. As a technology-driven company, T-MAXIMUM Pharmaceutical will continue to uphold a rigorous and pragmatic scientific approach, steadily advancing the clinical development of MT027. We remain committed to breaking new ground in the unexplored landscape of solid tumor cell therapy and using the power of science to win more time for patients.”

About MT027

MT027 is an “off-the-shelf” allogeneic CAR-T product sourced from healthy donors and designed to target B7-H3 for the treatment of recurrent glioblastoma. As an allogeneic therapy, MT027 enables large-scale manufacturing and cryopreservation, allowing patients to receive treatment rapidly without the delays associated with autologous cell production—an advantage that can be critical for individuals facing fast-progressing and life-threatening diseases.

Unlike many industry peers relying on lentiviral or retroviral vectors, T-MAXIMUM Pharmaceutical has achieved a major advancement during the product’s transition to registration-oriented clinical development—establishing a fully non-viral gene-editing platform. This innovation enhances product safety while improving manufacturing precision and controllability, representing the next generation of cell therapy engineering.

CAR-T therapies have revolutionized treatment for hematologic malignancies; however, progress in solid tumors has been notably slower—particularly in glioblastoma, where the blood-brain barrier, intratumoral heterogeneity, and immunosuppressive microenvironment pose unique challenges. FDA IND clearance enabling MT027 to enter Phase II clinical evaluation represents a milestone step in advancing allogeneic CAR-T technology toward one of the most difficult solid tumor indications.

Leveraging its mature allogeneic technology platform, T-MAXIMUM Pharmaceutical is concurrently developing additional clinical programs targeting brain metastases and other solid tumors, further expanding its therapeutic pipeline.

About Glioblastoma

Glioblastoma (GBM) is among the most aggressive and lethal cancers of the central nervous system, often referred to as the “Mount Everest” of neurosurgery. Despite widespread adoption of the standard Stupp regimen, median overall survival remains only 14–16 months, with a five-year survival rate below 5%. For patients with recurrent glioblastoma, treatment options are even more limited, with median survival typically less than 6–9 months. There remains a profound unmet medical need in this area.

Since its founding, T-MAXIMUM Pharmaceutical has focused its research and development strategy on addressing these unmet needs, deliberately steering away from highly competitive hematologic indications to confront the formidable challenge of glioblastoma. This regulatory achievement validates the feasibility and potential of the company’s platform.

About T-MAXIMUM Pharmaceutical

T-MAXIMUM Pharmaceutical is an innovative biotechnology company dedicated to the development of allogeneic, off-the-shelf cell therapies, with a mission to address diseases for which there are currently no effective treatments. The company brings together a seasoned team with expertise in immunotherapy, gene editing, and biopharmaceutical industrialization. Leveraging its fully proprietary gene-edited allogeneic immune cell platform, T-MAXIMUM has successfully overcome key challenges in allogeneic cell therapy, including graft-versus-host disease (GvHD) and immune rejection, enabling durable in-vivo persistence and therapeutic efficacy of CAR-T cells.

T-MAXIMUM is currently focused on late-stage malignant tumors, and its lead program for recurrent glioma has received clearance to enter Phase II clinical trials. Over the next three years, the company aims to advance at least one product toward marketing approval and progress multiple programs into Phase II clinical development.

Guided by the principles of integrity, innovation, and collaborative excellence, T-MAXIMUM Pharmaceutical remains committed to clinical value and original innovation. The company continues to pioneer breakthroughs in solid tumor cell therapy, striving to bring new hope to patients with diseases lacking effective treatment options.

Slow Boat Sinks in Mekong River Near Pak Ou Cave in Luang Prabang

By
Thongsavanh Souvannasane
-
A slow boat traveling from Pakbeng to Luang Prabang sank in the Mekong River near Tham Ting (Pak Ou) Cave in Pak Ou district around 3:18 to 3:27 PM on 18 December. (Photo supplies:

Authorities released a report on the Luang Prabang slow boat sinking. The report was dated 19 December but made public on 22 December.

According to the report, on 18 December at 9:30 AM, a boat with license number 0120, owned by a man named Ken from Hang Yai village, Chomphet district, Luang Prabang Province, departed from Pak Beng district, Oudomxay Province, heading to Donmai village in Luang Prabang City.

At around 3:45 PM, near Pak Ou (Tham Ting) Cave, the boat reportedly hit underwater rocks and sank about 20 minutes later. The report noted that the maritime buoyage system, which guides boats safely and marks hazards, had been damaged by previous boats. This may have caused the driver to misnavigate and hit the rocks.

There were 147 people on board, including 118 foreigners and 29 Lao nationals (25 passengers and 4 crew members). A motorbike and some passengers’ luggage also sank with the boat.

On 22 December, Lao media reported that rescue teams recovered the body of a woman named Pany Her, a resident of Khokaek village, Hongsa district, Xayyabouly Province, near Xanghai village, Pak Ou District, Luang Prabang Province.

Her two children, who were also on the boat, are still missing. Rescue teams are actively working to locate them.

The Ministry of Public Works and Transport officially reported that a slow boat sank near Pak Ou (Tham Ting) Cave in Luang Prabang on 18 December after striking underwater rocks.
The Ministry of Public Works and Transport officially reported that a slow boat sank near Pak Ou (Tham Ting) Cave in Luang Prabang on 18 December after striking underwater rocks.

Luang Prabang Slow Boat Sinking

A slow boat traveling from Pakbeng to Luang Prabang sank in the Mekong River near Tham Ting (Pak Ou) Cave in Pak Ou district around 3:18 to 3:27 PM on 18 December. 

The boat, carrying approximately 120 passengers, reportedly hit underwater rocks and sand about 25 km north of Luang Prabang City. No deaths have been officially reported so far. 

However, passenger Anna-Maria Dimitrova, a 29-year-old Bulgarian woman traveling with her husband Lazar Harizanov, told the Laotian Times on 19 December that one local woman and two children were missing. 

She noted that, “There were just a few life jackets on board.”

“All tourists were saved by a passing tourist boat going to the caves. We have heard this from other tourists. The police have not shared any information on this,” Anna-Maria added. 

She is currently contacting authorities regarding her lost luggage,

Authorities in Luang Prabang are conducting a boat recovery operation using boats and a crane. 

According to the boat owner, most luggage remains on the sunken vessel. 

Polish passenger Mikolaj K., who was also on board, described the evacuation: “We were about one hour away from Luang Prabang when we suddenly heard a loud noise, and the boat began to wobble violently. People woke up in panic. Two local Lao passengers stood up with fear on their faces and hugged each other tightly. At that moment we realized something serious had happened, when the locals are afraid, you know the situation is dangerous.”

Mikoraj continued, “Water was entering the engine room, and panic spread quickly. People rushed to retrieve their luggage. Some passengers were crying, others were trying desperately to organize their belongings. As the boat continued to take on water, another boat approached, and local passengers began handing their children onto the rescue boat. Chaos erupted. Many jumped into the river and helped each other to safety. Despite the panic, passengers organized themselves as best as possible.”

“The boat eventually broke in the middle,” Mikolaj said. “Some people tore open the roof to search for anyone still inside, but fortunately, everyone had already escaped. We lost all our luggage except our documents, but we are extremely grateful that no lives were lost.”

Authorities in Luang Prabang launched a recovery operation using boats and a crane to retrieve the sunken vessel. According to the boat owner, most passenger luggage remained on board at the time of the recovery.

As of 21 December, Anna-Maria confirmed that she had successfully recovered her luggage.

Authorities

Local authorities are continuing recovery efforts and coordinating with the boat owner to retrieve remaining belongings and address possible compensation for affected passengers.

The Laotian Times has contacted the boat owner and Luang Prabang authorities for official comments but had not received a response at the time of publication.

Further updates will be provided as more information becomes available.

Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73

By
Advertorial Desk
-

BEIJING, SHANGHAI and BOSTON, Dec. 21, 2025 /PRNewswire/ — Jacobio Pharma (1167.HK,) today announced that it has entered an agreement with AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E73. AstraZeneca will receive exclusive development and commercialisation rights outside of China, while Jacobio and AstraZeneca will jointly develop and commercialise JAB-23E73 in China.

Under the terms of the agreement, Jacobio will receive an upfront payment of US$100 million, and is eligible for additional development and commercial milestone payments of up to US$1.915 billion, as well as tiered royalties on net sales achieved outside of China. AstraZeneca will be responsible for all clinical development, regulatory submissions, and commercialization activities for JAB-23E73 outside of China. 

Yinxiang Wang Ph.D., Chairman and Co-CEO of Jacobio Pharma, commented: “We are delighted to partner with AstraZeneca. This collaboration marks a significant step forward as we bring our world-class programs to the global stage and maximize the value of our R&D innovation. We are committed to providing breakthrough treatments and improving survival for patients, including those with KRAS-mutated cancers, across the world.”

Matt Hellmann, Senior Vice President, Early Oncology and Precision Medicine, Oncology R&D, AstraZeneca, said: “KRAS is one of the most important oncogenes in cancer, with KRAS-mutated tumours driving profound unmet need for patients with pancreatic, colorectal and lung cancers. By advancing KRAS inhibitors like JAB-23E73, and in combination with our diverse oncology portfolio, we aim to accelerate the development of new treatment regimens that have the potential to transform outcomes for patients.”

JAB-23E73 is an innovative Pan-KRAS inhibitor developed using Jacobio’s induced allosteric drug discovery platform, designed to target multiple KRAS mutation subtypes. KRAS is the most frequently mutated oncogene in human cancers, present in approximately 23% of all patients. JAB-23E73 is being evaluated in Phase I trials in both China and the United States, where early signs of anti-tumor activity have been observed.

This agreement strengthens Jacobio’s financial position, accelerates the global development efforts, and expands our presence in the global oncology innovation ecosystem.

Jacobio will continue to delve into the KRAS pathway, advance tADCs with KRAS inhibitors as payloads, develop differentiated drugs targeting more KRAS mutation types, and drive forward its next immuno-oncology programs, including our STING-based iADC platform.

About Jacobio Pharma

Jacobio Pharma (1167.HK) is committed to providing breakthrough treatments for patients. With an induced allosteric drug discovery platform, the company’s core projects focus on the KRAS pathway and STING pathway. The company envisions becoming a global leader in research and development, fostering strategic partnerships to drive innovation. Jacobio’s R&D centers are located in Beijing and Shanghai (China), and Boston (USA). Clinical trials are conducted at over 180 sites in China, more than 30 sites in the USA, and more than 10 sites across several European countries.
For more information, please visit: http://www.jacobiopharma.com

In-Demand Employment Sectors: SIM Equips Singapore’s Workforce for the Future Economy

By
Advertorial Desk
-

SINGAPORE – Media OutReach Newswire – 21 December 2025 – Singapore’s job market is undergoing rapid transformation, driven by digitalisation, sustainability imperatives, and demographic shifts. The challenge for graduates and professionals lies in maintaining relevance within industries that are shaping tomorrow’s economy. The Singapore Institute of Management (SIM) plays a pivotal role in this development, equipping learners with critical skills and internationally recognised certifications sought by employers.

Growth Sectors Driving Singapore’s Economy

According to the Ministry of Manpower’s Labour Market Report (Q2 2025), resident employment continues to expand in Health & Social Services, while demand for roles in Information & Communications Technology (ICT) and sustainability-related fields remains robust despite global uncertainties. Job vacancies reached 76,900 in June 2025, surpassing the number of jobseekers, with a ratio of 1.35 vacancies per unemployed person—underscoring sustained demand for skilled talent.

Singapore’s Smart Nation and Green Plan strategies highlight key growth sectors including the digital economy (AI, data analytics, cybersecurity, cloud computing), finance and fintech (green finance, blockchain, digital banking), healthcare and life sciences (driven by aging demographics and biomedical innovation), and sustainability (ESG consulting and renewable energy)

SIM’s Industry-Aligned Programmes

SIM addresses the needs of Singapore’s fastest-growing sectors through two key business units: SIM Global Education (SIM GE) and SIM Academy (SIMA).

SIM GE collaborates with leading universities to deliver degree programmes in high-demand areas, such as:

  • Bachelor of Science (Honours) in Data Science and Business Analytics (University of London) – preparing graduates for careers in data analytics and machine learning
  • Bachelor in Computer Science (Big Data and Artificial Intelligence) (University of Wollongong) – developing expertise in cybersecurity and generative AI
  • Bachelor of Business, Majors in Economics, Finance etc (RMIT University) – enabling roles in finance

SIM Academy complements these academic pathways with professional development courses for upskilling and reskilling, including the Starting and Managing Corporate Sustainability, designed to empower professionals to lead ESG initiatives aligned with Singapore’s Green Plan 2030. These offerings combine academic rigor with practical certifications, internships, and industry-aligned projects, ensuring competitiveness in Singapore’s evolving job market.

Alumni Success Pathways

Graduates from SIM’s cybersecurity-related programmes come from a wide range of educational and professional backgrounds, reflecting the diversity of talent entering Singapore’s growing digital sector. Many begin their learning journeys with different motivations, whether to upskill for emerging roles, pivot from adjacent fields or pursue deeper specialisation in cybersecurity.

Some learners are inspired to pursue formal training after encountering real world risks, such as online fraud or data breaches. Others choose to build on existing technical foundations to take on more specialised responsibilities in national and enterprise cybersecurity functions. Through industry-aligned curricula, practical exposure and professional networks, SIM enables these learners to strengthen their competencies in areas such as threat intelligence, AI-enabled defence and cloud security.

These varied pathways highlight how SIM programmes support both early-career and mid-career professionals in progressing to roles within high-demand sectors, as well as further studies at reputable institutions. The outcomes reflect the value of accessible, skills focused education in developing the cybersecurity workforce needed to support Singapore’s transformation into a resilient and digitally driven economy.

Looking Ahead

Singapore’s economic future depends on a workforce that is agile, skilled, and prepared for change. SIM remains a catalyst in this transformation, offering programmes and professional courses aligned with national growth sectors and global trends. By combining academic excellence with practical industry exposure and showcasing alumni who have successfully transitioned into high-demand fields, SIM demonstrates how education drives employability and innovation.

References:

  1. Labour Market Report 2Q 2025 – https://www.mom.gov.sg/newsroom/press-releases/2025/0917-labour-market-report-2q-2025
  2. Smart Nation Vision – https://www.smartnation.gov.sg/about/our-vision/smart-nation-vision/
  3. A city of Green Possibility – https://www.greenplan.gov.sg/
  4. Green Fintech – https://www.mas.gov.sg/development/fintech/Green-FinTech?
  5. Bachelor of Science (Honours) in Data Science and Business Analytics – https://www.sim.edu.sg/degrees-diplomas/programmes/programme-listing/bachelor-of-science-honours-data-science-and-business-analytics
  6. Bachelor of Computer Science (Artificial Intelligence and Big Data) – https://www.sim.edu.sg/degrees-diplomas/programmes/programme-listing/bachelor-of-computer-science-artificial-intelligence-and-big-data
  7. Bachelor of Business – https://www.sim.edu.sg/degrees-diplomas/programmes/programme-listing/bachelor-of-business
  8. Starting and Managing Corporate Sustainability – https://www.sim.edu.sg/professional-development/courses/course-listing/starting-and-managing-corporate-sustainability

Hashtag: #SIMGlobalEducation #SIMGE #GlobalEducation #InternationalDegree #CareerReady #FutureSkills

The issuer is solely responsible for the content of this announcement.

About the Singapore Institute of Management

The Singapore Institute of Management (SIM) is an International Institute of Higher Learning (IIHL) that empowers, uplifts and strengthens employability, at all seasons of life and starting points. Seeded by the Singapore Economic Development Board in 1964, SIM nurtures leaders with industry focused skills, knowledge and values to create impact in Singapore and Asia through globally recognised education and learning pathways.

SIM harnesses new knowledge, skills, and technology to provide skills-based learning experiences that enable students, professionals, and enterprises to Learn for Life and Thrive for Life. Through SIM Global Education (SIM GE) and SIM Academy, SIM supports diverse learning needs—offering higher education pathways and tailored learning journeys for working professionals and enterprises to adapt and grow in an ever-changing world.

With a steadfast commitment to transforming lives, SIM continues to be a catalyst for change across communities, inspiring learners to contribute meaningfully to society, and fostering progress in society.

For more information on the Singapore Institute of Management, visit .

The Grand Opening of Dreame Hong Kong Flagship Store Showcases Full Product Lineup

By
Advertorial Desk
-

HONG KONG, Dec. 21, 2025 /PRNewswire/ — Dreame Technology, a global tech company dedicated to innovation in smart home appliances, officially opened its first offline flagship store in Hong Kong. Since entering the Hong Kong market, Dreame has been steadily strengthening its local presence. The opening of this flagship store marks a significant milestone in the brand’s expansion within the region.

Located in the Tsim Sha Tsui District at Mira Place, the new store marks the first public showcase of Dreame’s two latest flagship stick vacuums — the S50 Station and V50 — while also offering an exclusive early hands-on trial of the H16 Pro Steam. Visitors can explore Dreame’s full range of smart cleaning and personal care solutions, including the Aqua 10 Pro Track and Aqua10 Roller robot vacuums, the Pocket Uni global-voltage high-speed hair dryer, and more. In addition, Dreame’s latest air purifier, the PM20, makes its official debut in Hong Kong.

Dreame HK
Dreame HK

New Flagship Stick Vacuum Debut: Introducing the Dreame’s First Tangle-Cut™ Motorized Dual Blades Technology

At the event, Dreame unveiled two new stick vacuums — the V50 and the S50 Station. Both models are equipped with Dreame’s breakthrough Tangle-Cut™ Motorized Dual Blades Technology, capable of cutting up to 210,000 strands of human or pet hair in a single cleaning session, ensuring truly zero tangling.

Utilizing aerospace-grade, dual-layer titanium-coated blades, the system features approximately 200 high-density serrated blades that rapidly intersect and shear hair at speeds of up to 2,000 cuts per minute, significantly enhancing cutting efficiency. This innovation effectively addresses the long-standing issue of hair tangling found in traditional roller brushes, enabling both pet-owning households and users with long hair to enjoy a truly hands-free cleaning experience.

Equipped with a 130,000 RPM high-speed motor delivering 210AW suction power, both models effectively remove fine dust and dirt from floor crevices. The 140° wide-angle illumination reveals hidden dust, making cleaning even more thorough. Users can also upgrade with the AquaCycle™ 2.0 Suction-Washing Head, which uses electrolyzed water for sterilization and Dreame’s unique “Wash–Suction–Separation” process to efficiently handle both wet and dry messes.

Dreame S50 Station
Dreame S50 Station

S50 Station: Tangle-Cut™ Motorized Dual Blades with Auto Empty

As Dreame’s newest premium auto-empty stick vacuum in Hong Kong, the S50 Station features a multi-functional dust removal Hub that automatically performs dust collection and charging after each cleaning session. The 3L antibacterial dust bag, offering up to 100 days of long-term dust storage, significantly reduces maintenance while ensuring a hygienic home environment.

To ensure clean air out, the S50 Station is equipped with a multi-layer filtration system that delivers 99.99% whole-machine filtration efficiency, capturing particles as small as 0.1 µm. In addition, the HEPA H14 filter effectively traps bacteria and viruses, achieving a remarkable 99.99% filtration efficiency*. The Ultra Mode further enhances antibacterial performance before purified air is released back into the room. The smart indicator lighting clearly displays dust collection status, sterilization mode, and vacuum placement at a glance. With its high level of automation, hygiene, and efficiency, the S50 Station showcases Dreame’s leadership in high-end cleaning technology, delivering a smarter and healthier cleaning experience for Hong Kong households.

V50: Tangle-Cut™ Motorized Dual Blades with 1.6kg Lightweight

Designed for flexibility and ease of use, the V50 features an ultra-lightweight form factor paired with Tangle-Cut™ Motorized Dual Blades. Without the need for a base station, it is ideal for quick cleanups and everyday touch-ups, especially in small apartments or households that require frequent spot cleaning. With enhanced maneuverability and strong value for money, the V50 stands out as an excellent choice for users seeking a lightweight and versatile vacuum solution.

H16 Pro Steam: Dual-arm powered, 200°C Steam-enhanced clean

Now available for early experience at the flagship store and officially launching across Hong Kong on December 22, 2025, the H16 Pro Steam features industry-leading SaunaClean™ 200°C Steam Wash, combined with a 3000 mg/min high steam spraying to effectively dissolve grease, tackle stubborn stains, and achieve up to 99.9999% sterilization. Paired with ThermoRinse™ 90°C Hot Water Mopping, its dual-heat source floor washing is particularly suited for kitchens and dining areas with heavy grease buildup. The world’s first Dual-Arm Robotic AI DescendReach system delivers gap-free cleaning, zero water residue, and 100% tough stain removal, effectively minimizing cleaning blind spots and enhancing overall coverage and efficiency.

With enhanced true steam and hot water washing, the H16 Pro Steam provides faster, more effective, and more reliable home cleaning results.

Aqua 10 Pro Track: Mopping with 45°C Fresh Hot Water

Over the past two years, Dreame robot vacuums have redefined the market with industry-first innovations such as Robotic Retractable Legs, Dual Flex Arm Technology, VersaLift™ Navigation Technology, and advanced intelligent algorithms. These technologies have not only improved user experience but also earned Dreame the #1 market share in 18 countries worldwide. This year, Dreame takes robot vacuuming to the next level with its innovative Aqua 10 Pro Track and Aqua10 Roller, part of the fresh water cleaning series.

Dreame Aqua10 pro track
Dreame Aqua10 pro track

The Aqua 10 Pro Track, Dreame’s most advanced robot vacuum to date, introduces the industry’s first 45°C TrackSync™ Constant Hot Water Mopping, allowing the mop to clean and self-clean simultaneously with every rotation — solving the common problem of “the more you mop, the dirtier it gets.” Equipped with intelligent dirt detection and an extended track design for edge cleaning, it delivers deep cleaning performance even on heavy stains, oil spills, and tile grout. Beyond mopping, Aqua 10 Pro Track features 25,000Pa powerful suction, HyperStream™ Detangling DuoBrush, and Dual Flex Arm Technology for a comprehensive cleaning performance. OmniSight™ Navigation & Obstacle Avoidance and ProLeap™ 6cm Obstacle Cleaning ensure smooth movement across thresholds and carpets. The all-in-one smart base station takes the cleaning experience to a whole new level of automation. From ThermoHub™ 100°C Mop Self-Cleaning and Mop and Dust Bag Auto-Drying to UV sterilization, Auto Solution Refilling, and 100 Days Auto-Empty, it handles all maintenance in a single step — delivering a more convenient, hygienic, and intelligent whole-home cleaning solution.

Pocket Uni: The Ultimate “Travel Anywhere” Styling Tool

A Hong Kong fan favorite, the globally compatible 100–240V foldable high-speed hair dryer Pocket Uni has sold over 10,000 units in Hong Kong since launch. Weighing only 330g, its triple-fold design makes it ideal for travel and business trips. Powered by a 110,000 RPM high-speed motor, it delivers fast drying and styling with strong, stable airflow. Plasma Ion Concentration reduces frizz and enhances hair shine, while the upgraded SmartVolt™ Global Voltage Compatible ensures seamless use worldwide. The compact hair dryer also includes a Unfrizz Nozzle and Curling Barrels for versatile styling anytime, anywhere.

Dreame Pocket uni
Dreame Pocket uni

PM20：Dreame Hong Kong’s First All-in-One Smart Air Purifier

Dreame officially launches its first air purifier in Hong Kong, the PM20, which combines cooling and heating with intelligent air purification. In summer, it rapidly circulates air to deliver a refreshing flow of cool, clean air. In winter, it heats up in just three seconds, instantly filling the home with comfortable warmth even during cold weather.

Powered by jet airflow technology and a dual-way air outlet design that directs airflow both upward and forward, the PM20 delivers far-reaching airflow of up to 10 meters and a CADR of 400 m³/h, ensuring more uniform air circulation and comprehensive purification across the home.

The PM20 is equipped with a 4-Layer Filtration System, featuring an high-efficiency composite filter, an activated carbon layer, and an MnO₂ catalytic decomposition filter. Working together, the system effectively captures ultra-fine particles and allergens while continuously breaking down formaldehyde and other harmful gases, helping to maintain cleaner, healthier indoor air without the need for frequent filter replacement. Combined with intelligent environmental sensing and App connectivity, the PM20 allows users to monitor indoor air quality in real time, delivering a smart, hygienic, and comfortable living environment for the entire home.

Dreame PM20
Dreame PM20

Grand Opening Promotions

To celebrate the launch, Dreame will offer limited-time discounts, exclusive member benefits, and an opening raffle.

About Dreame

Established in 2017, Dreame Technology is an innovative consumer product company that focuses on smart home appliances with the vision to empower lives through technology. Follow us on Facebook and Instagram.

For more information, visit dreametech.com.hk

Christmas at Arspura: Year-End Savings and a New Range Hood Lineup

By
Advertorial Desk
-

LOS ANGELES, Dec. 21, 2025 /PRNewswire/ — Arspura, a premium kitchen ventilation brand, is celebrating the Christmas season with a limited-time Christmas range hood sale designed for homeowners planning a holiday kitchen upgrade. 

Why Upgrade Your Range Hood for Holiday Cooking

Christmas is when your range hood works its hardest. Multiple dishes on the stove, long hours of simmering, and frequent meals can overwhelm outdated or underpowered ventilation. A high-quality range hood helps capture smoke, grease, and odors at the source, so your living room smells like the holiday tree and dessert – not last night’s cooking.

A good range hood also helps reduce heat build-up around the cooktop, protects cabinets and walls from long-term grease stains, and creates a more pleasant space for whoever is in charge of the holiday menu. Upgrading at Christmas means your kitchen is ready for this season’s gatherings and for a full year of everyday cooking ahead.

The flagship Arspura P1 high-airspeed range hood now comes with $200 OFF, free professional installation, and a random holiday gift, when customers apply promo code XMAS at checkout.

Christmas Range Hood Sale for Festive Home Makeovers

This Christmas, Arspura is making it easier for homeowners to refresh their kitchens before guests arrive. The holiday campaign centers on the flagship P1 IQV hood, designed to handle intense festive cooking while keeping the air fresher and the space more comfortable.

To reward customers planning a holiday upgrade, Arspura is offering a limited-time Christmas P1 bundle with:

  • ¥200 OFF
  • Free professional installation (normally $199–$299, kitchen remodeling not included)
  • One random gift


P1 Range Hood: Built for Holiday-Ready Kitchens

  • High-airspeed suction for heavy cooking: Quickly clears smoke, steam, and strong cooking odors during searing, stir-frying, roasting, and deep-frying.
  • Fresher air for guests and family: Helps the kitchen and living area smell like celebration, not lingering grease or spicy fumes after big holiday dinners.
  • Practical, low-maintenance upgrade: Designed for everyday cooking and peak holiday use, with performance that lasts beyond the season.

With powerful performance, a modern look that suits today’s kitchens, and a value-packed Christmas bundle, upgrading to P1 becomes a practical way to complete a festive home makeover before the new year.


See how Arspura keeps holiday cooking smoke-free while you enjoy a fresher, more comfortable kitchen this Christmas.

New Range Hood Lineup: F1 & P2 With Exclusive Preorder Benefits

Alongside the P1 offer, Arspura is rolling out new F1 and P2 range hoods, both part of the Christmas bundle (free installation + random gift), with preorder customers also enjoying early-bird pricing and priority delivery.

F1 Cabinet-Friendly Range Hood: Designed for Modern Kitchens

Within the new lineup, the F1 30″ range hood is engineered for kitchens where space, cabinetry, and style all matter.

  • Cabinet-friendly dimensions: Fits common cabinet widths and depths for easy replacement.
  • Space-efficient design: Streamlined form keeps the cooktop area open — ideal for compact kitchens.
  • Perfect for upgrades: Balances power, compatibility, and clean design for refresh projects.

With F1, Arspura combines strong performance and everyday practicality for long-term kitchen updates.

P2 Range Hood: Open-Space Comfort for Cooking

  • Top-suction design keeps the area in front of you open for a more comfortable cooking experience.
  • High-airspeed (up to 15 m/s) tackles heavy grease and strong odors with ease.
  • Quiet, efficient operation to keep the kitchen comfortable during daily cooking.

Better Air, Pure Life

Arspura’s mission is to help families cook freely and breathe easier, combining high-airspeed smoke capture with thoughtful design and everyday usability. With the Arspura Christmas range hood sale, homeowners can turn a practical appliance purchase into a long-lasting gift: a cleaner, quieter, and more welcoming kitchen all season long.

For more information or to redeem the Christmas promotion or product lineup, please visit arspura.com（https://arspura.com/）.

Laos, Vietnam Deepen Economic Diplomacy with Focus on Digital Economy

By
Laotian Times
-
This photo is used for representational purpose only.

Officials from Laos and Vietnam met in Hanoi on 18–19 December to strengthen economic diplomacy, with a strong focus on digital economy development and government digital transformation.

The Laos delegation was led by Somboun Sihanat, Director of the Department of Economics at the Ministry of Foreign Affairs, alongside meetings linked to the 12th Ministerial Political Consultation between the two countries.

During the talks, both sides reviewed progress under existing economic diplomacy agreements and discussed future cooperation plans. Vietnam shared its experience in digital transformation across government and business sectors, offering practical insights for Laos as it expands its own digital systems.

Vietnamese sources said the meetings formed part of broader efforts to strengthen economic connectivity and ensure high-level agreements between the two countries are effectively implemented. Both sides reviewed progress under existing economic diplomacy agreements and discussed cooperation plans for the coming years.

Officials also exchanged views on regional and global economic developments, as well as ways digital tools could support diplomatic work, including trade promotion and investment facilitation.

As part of the visit, the Laos delegation toured an industrial development zone in Hai Phong Province to learn from Vietnam’s industrial and manufacturing experience.

Vietnamese media described the consultations as taking place in a spirit of close cooperation, with an emphasis on translating long-standing political ties into concrete economic results that benefit both countries.

1...1,6421,6431,644...6,679Page 1,643 of 6,679